Israeli drug development company Intec Pharma, which has developed the Accordion Pill(TM) gastric retention technology, has signed an agreement with two leading North American dosage form manufacturers in order to scale-up the company's manufacturing platform. The two manufacturers are Canadian company BioEnvelop Agro Inc. and US company Tapemark.
Announcing the agreement Intec Pharma CEO Efi Cohen-Arazi said, "The signing of these agreements means that we can move ahead immediately with laying the groundwork for the mass production of our pipeline products. Tapemark is a world leader in large-scale pharmaceutical production. Together with BioEnvelop they have the expertise, know-how and infrastructure required to get our products quickly to market.”
BioEnvelop has developed breakthrough technologies for the manufacture of dissolvable capsules containing active ingredients. Tapemark is a veteran manufacturer of drug packaging systems for the medical, pharmaceutical, and consumer products markets, in compliance with FDA and other regulatory standards.
Intec Pharma plans to launch a series of super-generic drugs (generic drugs with the addition of a patent-protected mechanism that gives the product as a whole renewed exclusivity) that leverage the unique drug delivery capabilities offered by the Accordion Pill technology. The company recently decided to develop these drugs independently, without cooperating with large pharmaceuticals companies, which is why it also needs the curent manufacturing agreement.
Intec Pharma is set to begin Phase I clinical trials of its products.
Published by Globes [online], Israel business news - www.globes.co.il - on June 18, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006